• Research
    • Labs
      • Gumrukcu Lab
        • Dr. Serhat
        • Lab Members
        • Publications
    • Fields
      • Cancer
      • Infectious Diseases
  • Clinical
    • Diseases
    • Clinical Studies
    • Experimental Treatments
  • Collaborations
  • About Us
    • Purpose
    • History
    • Leadership
    • Faculty
      • Serhat Gumrukcu, MD, PhD
      • Phillip Musikanth, MD
      • Tung Nguyen
      • David Hardy, MD
      • Shimon Slavin, MD
      • Charles Sophy, DO
  • News
  • Contact
Welcome to Seraph Research Institute
Facebook
Twitter
Youtube
Instagram
Pinterest
  • Research
    • Labs
      • Gumrukcu Lab
        • Dr. Serhat
        • Lab Members
        • Publications
    • Fields
      • Cancer
      • Infectious Diseases
  • Clinical
    • Diseases
    • Clinical Studies
    • Experimental Treatments
  • Collaborations
  • About Us
    • Purpose
    • History
    • Leadership
    • Faculty
      • Serhat Gumrukcu, MD, PhD
      • Phillip Musikanth, MD
      • Tung Nguyen
      • David Hardy, MD
      • Shimon Slavin, MD
      • Charles Sophy, DO
  • News
  • Contact
Menu
  • Research
    • Labs
      • Gumrukcu Lab
        • Dr. Serhat
        • Lab Members
        • Publications
    • Fields
      • Cancer
      • Infectious Diseases
  • Clinical
    • Diseases
    • Clinical Studies
    • Experimental Treatments
  • Collaborations
  • About Us
    • Purpose
    • History
    • Leadership
    • Faculty
      • Serhat Gumrukcu, MD, PhD
      • Phillip Musikanth, MD
      • Tung Nguyen
      • David Hardy, MD
      • Shimon Slavin, MD
      • Charles Sophy, DO
  • News
  • Contact
GIVE
Welcome to Seraph Research Institute
Facebook
Twitter
Youtube
Instagram
Pinterest
  • Research
    • Labs
      • Gumrukcu Lab
        • Dr. Serhat
        • Lab Members
        • Publications
    • Fields
      • Cancer
      • Infectious Diseases
  • Clinical
    • Diseases
    • Clinical Studies
    • Experimental Treatments
  • Collaborations
  • About Us
    • Purpose
    • History
    • Leadership
    • Faculty
      • Serhat Gumrukcu, MD, PhD
      • Phillip Musikanth, MD
      • Tung Nguyen
      • David Hardy, MD
      • Shimon Slavin, MD
      • Charles Sophy, DO
  • News
  • Contact
Menu
  • Research
    • Labs
      • Gumrukcu Lab
        • Dr. Serhat
        • Lab Members
        • Publications
    • Fields
      • Cancer
      • Infectious Diseases
  • Clinical
    • Diseases
    • Clinical Studies
    • Experimental Treatments
  • Collaborations
  • About Us
    • Purpose
    • History
    • Leadership
    • Faculty
      • Serhat Gumrukcu, MD, PhD
      • Phillip Musikanth, MD
      • Tung Nguyen
      • David Hardy, MD
      • Shimon Slavin, MD
      • Charles Sophy, DO
  • News
  • Contact
GIVE

CANCER

Every cancer starts with a single cell that is able to evade the immune system’s surveillance. In this cloaked state, the immune system is unable to launch an attack on the disease. This results in the continuous and excessive growth of the cancer cells, which results in the generation and progression of malignant tumors.

Hypothetically, a cure can be accomplished if the patient’s immune system is taught to effectively identify and kill the elusive cancer cells that evade or repel the immune cells. As a general concept “immunotherapy” governs different strategies and treatment modalities to accomplish this feat.

HEMATOLOGICAL MALIGNANCIES

In our cancer research, we focus on cancer biology, basic immunology, cancer immunology, cancer’s immune-evasion mechanisms, and host immune defense systems to try to leverage the latest developments and the information collected in fundamental science research to create innovative modalities for the treatment of cancer. This includes developing targeted and cell-mediated immunotherapy, including vaccines, oncolytic viruses, and modalities – especially using cancer-targeted immune system cells and other personalized tumor-targeted approaches for the treatment of patients with cancer at the risk of disease recurrence, or at a stage known to be resistant to conventional treatments.

HEMATOLOGICAL MALIGNANCIES

In our cancer research, we focus on cancer biology, basic immunology, cancer immunology, cancer’s immune-evasion mechanisms, and host immune defense systems to try to leverage the latest developments and the information collected in fundamental science research to create innovative modalities for the treatment of cancer. This includes developing targeted and cell-mediated immunotherapy, including vaccines, oncolytic viruses, and modalities – especially using cancer-targeted immune system cells and other personalized tumor-targeted approaches for the treatment of patients with cancer at the risk of disease recurrence, or at a stage known to be resistant to conventional treatments.

Our cancer-related research programs include gene-modified cell therapies in hematological and solid tumor cancers, personalized cancer vaccines, host cellular, and molecular defense systems, cancer-specific immunogenicity, and the mechanisms of activation, inhibition, and cross-communication of innate and adaptive immune systems in cancer.

cns-malignancies

CNS MALIGNANCIES

Most common primary central nervous system (CNS) malignancies are gliomas.  A primary CNS tumor is often graded as either low grade or high grade. A low-grade tumor is a slow-growing tumor, which can later become a high-grade tumor. A high-grade tumor is usually a fast-growing tumor. CNS tumors are often particularly challenging to treat, because their structure and/or location makes them impossible to surgically remove.

Seraph Research Institute focuses on new strategies designed to reprogram the immune system to overcome the cancer’s immune evasive or immune-regulatory mechanisms in the nervous system. We also study the potential immunotherapy (graft-versus-tumor effect) properties of allogeneic bone marrow transplant and gene-modified autologous bone marrow transplant in carefully designed pre-clinical experiments to explore the clinical potential of bone marrow transplants in CNS malignancies.

Solid Tumor Cancers

SOLID TUMOR CANCERS

Our research in solid tumor cancers is driven by several scientific goals, including:
  • define and understand the molecular mechanisms behind the immune-evasion properties of the solid tumor micro environment
  • understand the mechanisms of inhibition of the host cellular immune response in cancer
  • elucidate the cellular and molecular alterations that initiate tumor generation and support cancer cell proliferation and persistence
  • improve existing therapeutic regimens and ongoing translational and clinical research from our basic science discoveries
  • accelerate the translational science and help individuals have access to new and innovative clinical modalities
  • solid tumor cancer research mainly focuses on the cancer-specific immunogenic effects of adoptive cell therapies and cell-based cancer vaccines.

HEMATOLOGICAL MALIGNANCIES

Hematologic cancers are the cancers that occur in the immune system cells or in blood-forming organs, like bone marrow and lymph nodes. Seraph Research Institute focuses on harnessing the knowledge, experience and efficacy of the existing standard treatment models – such as  stem cell transplantation combined with novel methods like gene therapies – to transform the existing standard of care to a more evolved, less toxic version of itself.

Our team collaborates in research with leading international experts in the field to bring pioneering discoveries into hematological malignancies and new and improved stem cell transplant methods to early-phase clinical stage to potentially change the standard of care of cancer for the coming generations.

DNA
DNA

HEMATOLOGICAL MALIGNANCIES

Hematologic cancers are the cancers that occur in the immune system cells or in blood-forming organs, like bone marrow and lymph nodes. Seraph Research Institute focuses on harnessing the knowledge, experience and efficacy of the existing standard treatment models – such as  stem cell transplantation combined with novel methods like gene therapies – to transform the existing standard of care to a more evolved, less toxic version of itself.

Our team collaborates in research with leading international experts in the field to bring pioneering discoveries into hematological malignancies and new and improved stem cell transplant methods to early-phase clinical stage to potentially change the standard of care of cancer for the coming generations.

solid-tumor-cancers

Solid Tumor Cancers

Coming Soon

hematological-cancers

Hematological Cancers

Coming Soon


seraph research institute

Seraph Research Institute
2080 Century Park East
Suite 710
Los Angeles, CA 90067
United States

424-388-1025

310-747-6732

info@seraphinstitute.org

RECENT FEATURES

blue-iv-drip

Gene modified CD34+ cells with increased ALDH1 expression confers in vitro protection against cyclophosphamide

February 24, 2021
Important-Role-of-gd-T-Cells-in-Anti-SARS-CoV-2-Immune-Response2

Important Role of gd T Cells in Anti-SARS-CoV-2 Immune Response

November 13, 2020

JOURNAL ARTICLES

Glutamate-Cysteine Ligase Modifie Subunit Overexpression Confers Resistance Against Busulfan

September, 2020

Gene Modified CD34+ cells with increased ALDH1 expression confers in virtro protection against cyclophosphamide

August, 2020

NEWSLETTER

For research updates and news, please enter your email address in the field below.

©2020 | Seraph Research Institute

Individualized Research                  Team                   Give